KALV vs BDTX vs PRAX vs KALA vs XOMA

For growth investors, XOMA Royalty Corp.

(XOMA) is the stronger pick with 83. 1% revenue growth year-over-year, versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). Black Diamond Therapeutics, Inc. (BDTX) offers the better valuation at 7. 0x trailing P/E, making it the more compelling value choice. Analysts rate KalVista Pharmaceuticals, Inc. (KALV) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Black Diamond Therapeutics, Inc.

(BDTX) is the cheapest at 7. 0x versus XOMA Royalty Corp. at 28. 3x.

Over the past 5 years, XOMA Royalty Corp.

(XOMA) delivered a total return of +30. 0%, compared to -100. 0% for KALA BIO, Inc. (KALA). Over 10 years, the gap is even starker: XOMA returned +186. 7% versus KALA's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), KalVista Pharmaceuticals, Inc.

(KALV) is the lower-risk stock at 0. 82β versus Black Diamond Therapeutics, Inc. 's 2. 66β — meaning BDTX is approximately 222% more volatile than KALV relative to the S&P 500. On balance sheet safety, Praxis Precision Medicines, Inc. (PRAX) carries a lower debt/equity ratio of 0% versus 3% for KALA BIO, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), XOMA Royalty Corp.

(XOMA) is pulling ahead at 83. 1% versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). On earnings-per-share growth, the picture is similar: XOMA Royalty Corp. grew EPS 188. 5% year-over-year, compared to -32. 0% for Praxis Precision Medicines, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

XOMA Royalty Corp.

(XOMA) is the more profitable company, earning 60. 8% net margin versus -141. 1% for KALA BIO, Inc. — meaning it keeps 60. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: XOMA leads at 21. 8% versus -150. 6% for KALA. At the gross margin level — before operating expenses — BDTX leads at 99. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for KALA: 21861.

5% to $18. 25.

In this comparison, XOMA (0.

7% yield) pays a dividend. KALV, BDTX, PRAX, KALA do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, XOMA Royalty Corp.

(XOMA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 21), 0. 7% yield, +186. 7% 10Y return). KALA BIO, Inc. (KALA) carries a higher beta of 2. 09 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (XOMA: +186. 7%, KALA: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: KALV is a small-cap quality compounder stock; BDTX is a small-cap deep-value stock; PRAX is a small-cap quality compounder stock; KALA is a small-cap quality compounder stock; XOMA is a small-cap high-growth stock. XOMA pays a dividend while KALV, BDTX, PRAX, KALA do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.